<?xml-stylesheet type="text/xsl" href="https://emersonexchange365.com/cfs-file/__key/system/syndication/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><title>Faster Tech Transfer Unlocks Speed to Market</title><link>/services/b/implementbuild/posts/faster-tech-transfer-unlocks-speed-to-market-907645425</link><description>The rapid development of the COVID-19 vaccine has created a dramatic shift in the way the public and life sciences organizations view the manufacturing of pharmaceuticals. In a recent Q&amp;amp;A with Pharma Manufacturing , Nathan Pettus , president of Emerson</description><dc:language>en-US</dc:language><generator>Telligent Community 13</generator></channel></rss>